Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.
AffiliationMerseyside and Cheshire Cancer Registry, University of Liverpool, UK.
MetadataShow full item record
AbstractClassification of lymphoid malignancy has changed markedly in recent years and advances have been made in therapy. This study investigated the variations in treatment and survival of 1622 patients in a population-based registry. A total of 1009 cases of malignant lymphoma (ML) were classified according to the Kiel classification. Pathology review resulted in major diagnostic changes for 24% of cases. Of the ML cases, 39% had not had full staging procedures. Younger patients were more likely to have been treated with multiagent chemotherapy regimens, as were patients with B symptoms. Median survival for ML patients was 12 months for high-grade patients and more than 60 months for low-grade patients. Significant factors affecting the survival of ML patients were performance status, whether treatment had followed a recognised protocol, whether treatment had been carried out at a specialist oncology centre (SOC), grade of disease, stage, gender and age. The same factors had a significant effect on survival of the leukaemia patients, except for treatment at an SOC, which had a significant favourable effect on survival of acute lymphoblastic leukaemia (ALL) patients only. Median survival for patients with chronic lymphocytic leukaemia was 43 months and 7 months for ALL patients.
CitationTreatment and survival of lymphoid malignancy in the north-west of England: a population-based study. 1995, 72 (3):757-65 Br. J. Cancer
JournalBritish Journal of Cancer
- Recent trends in the treatment and prognosis of adult leukemia with characteristics of patients in Japan: transition during the fifteen years from 1971 to 1985.
- Authors: Suzuki H, Ota K, Ohno R, Masaoka T, Shibata H, Kimura I, Amaki I, Miura Y, Uzuka Y, Kawato M
- Issue date: 1989 Dec
- Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.
- Authors: Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, Leprisé PY, François S, Cony-Makhoul P, Harousseau JL
- Issue date: 1995 Feb 1
- Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
- Authors: Plosker GL, Figgitt DP
- Issue date: 2003
- [Lymphoblastic non-Hodgkin's lymphoma: estimation of the survival of patients with the disseminated form of the disease (stages III and IV) treated by the LSA2-L2 protocol].
- Authors: Pisón Garcés J, Buñuel Alvarez JC, Domínguez Fenollé MP, Castillo Laita JA, Cenarro Guerrero T, Monreal Gálvez MJ, Arana Navarro T, Hernández Gayá A
- Issue date: 1991 Dec
- A single unit lymphoma experience: outcome in a Cape Town academic centre.
- Authors: Wood L, Robinson R, Gavine L, Juritz J, Jacobs P
- Issue date: 2007 Aug